Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
61.34
-1.96 (-3.10%)
At close: Aug 20, 2026, 4:00 PM EDT
61.20
-0.14 (-0.23%)
Pre-market: Aug 21, 2026, 7:16 AM EDT

Vaxcyte Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Profit
----75-23-
Operating Income
-1,165-923.68-569.55-468.04-232.26-103.67
Net Income
-1,064-766.63-463.93-402.27-223.49-100.08
Earnings Per Share
-7.65-5.63-3.80-4.14-3.44-1.93
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,4871,5611,7471,080931.38245.97
Total Debt
115.45117.4871.1129.2217.9416.78
Net Cash (Debt)
1,3711,4431,6761,051913.44229.19
Net Cash Growth
-12.96%-13.88%59.48%15.06%298.55%-40.66%
Net Cash Per Share
9.8510.6113.7410.8214.084.41

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-881.23-655.58-452.63-296.79-170.6-121.39
Capital Expenditures
-39.84-56.97-119.16-67.88-5.84-6.56
Free Cash Flow
-921.07-712.55-571.79-364.67-176.44-127.95
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.